Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.

ABSTRACT: Treatment of high-risk patients is a major challenge in multiple myeloma. This is especially true for patients assigned to the gene expression profiling-defined proliferation subgroup. Although recent efforts have identified some key players of proliferative myeloma, genetic interactions and players that can be targeted with clinically effective drugs have to be identified in order to overcome the poor prognosis of these patients. We therefore examined maternal embryonic leucine zipper kinase (MELK) for its implications in hyper-proliferative myeloma and analyzed the activity of the MELK inhibitor OTSSP167 both in vitro and in vivoMELK was found to be significantly overexpressed in the proliferative subgroup of myeloma. This finding translated into poor overall surviva

SUBMITTER: Bolomsky A 

PROVIDER: S-EPMC5792277 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature